We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New WHO Tools Address Gaps in Antimicrobial Resistance Testing

By LabMedica International staff writers
Posted on 18 Nov 2026

Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly by antibiotic use in human healthcare, animal husbandry, and food production, contributing to infectious disease mortality worldwide. Despite the urgent need for effective prevention, accurate diagnostics, and responsible antibiotic use, new findings indicate that progress remains too slow to meet global targets.

The World Health Organization (WHO) has released two new tools intended to help countries strengthen diagnostic capacity for antimicrobial resistance. The first tool defines the tests that should be available across health care settings, from primary care centers to referral hospitals. The second compiles 73 laboratory procedures covering sample collection, pathogen identification and antibiotic susceptibility testing.


Image: A colored electron microscopy image of methicillin-resistant staphylococcus aureus (MRSA), a bacterium commonly targeted by broad-spectrum antibiotics (Image Credit: National Institute of Allergy and Infectious Diseases)
Image: A colored electron microscopy image of methicillin-resistant staphylococcus aureus (MRSA), a bacterium commonly targeted by broad-spectrum antibiotics (Image Credit: National Institute of Allergy and Infectious Diseases)

The tools were announced after a WHO investigation across 183 countries assessed progress in combating antimicrobial resistance. Nearly nine in 10 countries reported having a national action plan, compared with around four in 10 in 2017. However, only 42 countries reported having a plan that was financed, implemented and monitored.

Diagnostic access remains a major weakness in the response. Only 36% of countries had a national reference laboratory capable of testing for resistance in all bacteria and fungi monitored by WHO, compared with an 80% target for 2030. WHO also stated that 2023 global surveillance data showed one in every six laboratory-confirmed bacterial infections reported to the agency was resistant to antibiotics used for treatment. The agency estimated that antimicrobial resistance could cause about 39 million deaths between now and 2050.

“Antimicrobial resistance is widespread and threatening the future of modern medicine,” said Jean-Pierre Nyemazi, interim head of antimicrobial resistance at the WHO. “Unlike COVID-19, which was very visible, drug-resistant infections have been taking people's lives for years without us noticing it and raising the alarm as we should.”

“Countries are moving forward in every step, but progress still needs to be speeded up to reach the 2030 targets,” added Nyemazi.

Related Links
World Health Organization


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Latest Microbiology News

Complete Malaria Genomes Could Improve Species Identification and Surveillance
17 Nov 2026  |   Microbiology

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
17 Nov 2026  |   Microbiology

Automated Microbial Identification and Susceptibility System Gains FDA Clearance
17 Nov 2026  |   Microbiology